Show simple item record

dc.contributor.authorVan Wijmeersch, Bart
dc.contributor.authorSinger, Barry A
dc.contributor.authorBoster, Aaron
dc.contributor.authorBroadley, Simon
dc.contributor.authorFernández, Óscar
dc.contributor.authorFreedman, Mark S
dc.contributor.authorIzquierdo, Guillermo
dc.contributor.authorLycke, Jan
dc.contributor.authorPozzilli, Carlo
dc.contributor.authorSharrack, Basil
dc.contributor.authorSteingo, Brian
dc.contributor.authorWiendl, Heinz
dc.contributor.authorWray, Sibyl
dc.contributor.authorZiemssen, Tjalf
dc.contributor.authoret al.
dc.date.accessioned2019-11-12T01:29:41Z
dc.date.available2019-11-12T01:29:41Z
dc.date.issued2019
dc.identifier.issn1352-4585
dc.identifier.doi10.1177/1352458519881759
dc.identifier.urihttp://hdl.handle.net/10072/389059
dc.description.abstractBACKGROUND: Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. OBJECTIVE: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). METHODS: Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. RESULTS: Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). CONCLUSION: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. CLINICALTRIALS.GOV REGISTRATION NUMBERS: CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSage Publications
dc.publisher.placeUnited Kingdom
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto10
dc.relation.ispartofjournalMultiple Sclerosis Journal
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchcode1109
dc.subject.fieldofresearchcode1103
dc.subject.keywordsefficacy
dc.subject.keywordsmagnetic resonance imaging (MRI)
dc.subject.keywordsrelapsing–remitting multiple sclerosis (MS)
dc.subject.keywordsAlemtuzumab
dc.subject.keywordsdisability
dc.titleEfficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationVan Wijmeersch, B; Singer, BA; Boster, A; Broadley, S; Fernández, Ó; Freedman, MS; Izquierdo, G; Lycke, J; Pozzilli, C; Sharrack, B; Steingo, B; Wiendl, H; Wray, S; Ziemssen, T; Chung, L; Margolin, DH; Thangavelu, K; Vermersch, P, Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies., Multiple Sclerosis Journal, 2019, pp. 1-10
dcterms.licensehttps://creativecommons.org/licenses/by-nc/4.0/
dc.date.updated2019-11-08T02:23:00Z
dc.description.versionVersion of Record (VoR)
gro.description.notepublicThis publication has been entered into Griffith Research Online as an Advanced Online Version
gro.rights.copyright© The Author(s), 2019. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorBroadley, Simon


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record